Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CannaXR is a topical cream developed by MINO Labs that combines advanced nanotechnology with cannabidiol (CBD) in an extended-release formulation. It is designed to provide protective benefits against UVA-induced skin damage, targeting both visible and molecular markers of photoaging and DNA injury. In a pilot randomized clinical study (NCT05279495), CannaXR demonstrated significant reductions in erythema, epidermal thickening, sunburn cells, and biomarkers of free radical DNA damage after UVA exposure. The product aims to complement traditional sunscreens by focusing on reducing internal cellular damage associated with UV exposure, potentially lowering the risk of skin aging and UV-related cancers through its innovative drug delivery system[1][2].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on CannaXR.